Methods and therapies for treating atherosclerosis and/or hyperlipidemia using oligosaccharides

Abstract

The disclosure provides for therapies and methods to treat atherosclerosis and/or hyperlipidemia, and complications resulting therefrom, with compositions that comprise therapeutically effective amounts of one or more human milk oligosaccharides.

What is claimed is: 
     
         1 . A method of treating or attenuating atherosclerosis and/or hyperlipidemia in a subject in need thereof comprising administering a composition comprising an effective amount of two human milk-based oligosaccharides, wherein the composition comprises:
 (i) a human milk-based oligosaccharide selected from the group consisting of 3′-fucosyllactose, 2′-fucosyllactose, lacto-N-tetraose, lacto-N-neotetraose, lacto-N-fucopentaose I, lacto-N-fucopentaose II, lacto-N-fucopentaose III, and lacto-N-fucopentaose V; and   (ii) 3′-sialyllactose or 6′-sialyllactose.   
     
     
         2 . The method of  claim 1 , wherein composition comprises 3′-sialyllactose. 
     
     
         3 . The method of  claim 2 , wherein the composition comprises 6′-sialyllactose. 
     
     
         4 . The method of  claim 1 , wherein the composition comprises a nutritional product, food additive or dietary supplement. 
     
     
         5 . The method of  claim 1 , wherein the subject is a companion animal or pet. 
     
     
         6 . The method of  claim 1 , wherein the subject is a human subject. 
     
     
         7 . The method of  claim 1 , wherein the composition is a therapeutic composition. 
     
     
         8 . A method of treating or attenuating one or more complications associated with atherosclerosis and/or hyperlipidemia in a subject in need thereof comprising administering a therapeutically effective amount of a composition comprising an effective amount of two human milk-based oligosaccharides, wherein the composition comprises:
 (i) a human milk-based oligosaccharide selected from the group consisting of 3′-fucosyllactose, 2′-fucosyllactose, lacto-N-tetraose, lacto-N-neotetraose, lacto-N-fucopentaose I, lacto-N-fucopentaose II, lacto-N-fucopentaose III, and lacto-N-fucopentaose V; and   (ii) 3′-sialyllactose or 6′-sialyllactose.   
     
     
         9 . The method of  claim 8 , wherein the one or more complications associated with atherosclerosis and/or hyperlipidemia are selected from coronary artery disease, heart failure, myocardial infarction, aneurysm, stroke, arrhythmia, peripheral arterial disease, chronic kidney disease, end-stage renal disease, renal artery stenosis, central retinal artery occlusion, central retinal vein occlusion, branch retinal artery occlusion, branch retinal vein occlusion, erectile dysfunction, and mesenteric ischemia. 
     
     
         10 . The method of  claim 8 , wherein the administration of therapeutically effective amounts of the human milk-based oligosaccharides results in one of more of the following effects: a decrease in the incidence or severity of the atherosclerosis; a decrease in the size of aortic plaques; a decrease in the size of atherosclerotic lesions; a decrease in the plasma concentration for triglycerides; a decrease in the plasma concentration of cholesterol; a reduced incidence of complications resulting from atherosclerosis and/or hyperlipidemia; and/or an improvement in subject-reported outcomes as to the status of the subject's health condition. 
     
     
         11 . The method of  claim 8 , wherein the composition is a pharmaceutically acceptable composition comprising one or more pharmaceutically acceptable carriers and/or excipients. 
     
     
         12 . The method of  claim 11 , wherein the pharmaceutically acceptable composition is formulated for oral delivery. 
     
     
         13 . The method of  claim 12 , wherein the pharmaceutically acceptable composition is formulated as a powder that is soluble in an aqueous solvent, a tablet, a chewable tablet or gummy, a liquid filed capsule or a capsule. 
     
     
         14 . The method of  claim 11 , wherein the pharmaceutically acceptable composition is formulated for parenteral administration. 
     
     
         15 . The method of  claim 8 , wherein the composition is a non-human milk oral composition comprising 3′-sialyllactose. 
     
     
         16 . The method of  claim 8 , wherein the composition comprises a nutritional product, food additive or dietary supplement. 
     
     
         17 . The method of  claim 8 , wherein the subject is a companion animal or pet. 
     
     
         18 . The method of  claim 8 , wherein the subject is a human subject. 
     
     
         19 . The method of  claim 8 , wherein the composition is a therapeutic composition.